Collplant biotechnologies begins preclinical trial with commercial-size, regenerative breast implants

The current market for breast implants is estimated at $2.6 billion a year collplant expects the study to conclude by the first half of 2024 collplant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards a glp preclinical pivotal study with commercial size implants rehovot, israel , jan. 2, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3d-bioprinted, regenerative breast implants. currently, there are no commercial products that allow regeneration of soft tissues such as the breast.
CLGN Ratings Summary
CLGN Quant Ranking